** Shares of drugmaker United Therapeutics UTHR.O down 3.5% at $345 premarket
** Co posts quarterly adj profit of $6.19 per share, missing analysts' estimates of $6.31 per share, according to data compiled by LSEG
** However, co's Q4 revenue came in at $735.9 million on sales of its lung disorder inhaled-drug Tyvaso, slightly above estimates of $734.7 million
** Brokerage Leerink Partners says it appears that Tyvaso was not quite able to buck seasonal trends this quarter unlike a year ago
** The stock has risen ~60% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。